Acquiring Company
Hanmi Pharmaceutical Ltd
Acquired Company
Aptose Biosciences
South Korea
San DiegoBiotechnologyHealth CarePharmaceuticalpharmaceuticalsBiotechnologyHealth CareMedicalTherapeuticsresearchDescription
Hanmi Pharmaceutical Co. Ltd. has completed the acquisition of Aptose Biosciences, Inc., acquiring all issued common shares not owned by Hanmi. Shareholders of Aptose will receive C$2.41 cash per share, marking a 28% premium. The acquisition has received all necessary approvals and is set to be finalized by July 3, 2026.
Who to call at Hanmi Pharmaceutical Ltd, and when
When Hanmi Pharmaceutical Ltd changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Hanmi Pharmaceutical Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Hanmi Pharmaceutical Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Hanmi Pharmaceutical Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Hanmi Pharmaceutical Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Aptose Biosciences?
Aptose Biosciences was acquired by Hanmi Pharmaceutical Ltd, based in South Korea. The deal was reported on July 1, 2026. Hanmi Pharmaceutical Co. Ltd. is a biopharmaceutical company engaged in the research, development, manufacture, and marketing of innovative medicines with a focus on metabolic disorders, oncology, and rare diseases. Hanmi Pharmaceutical Ltd is privately held and operates in Biotechnology.
When did Hanmi Pharmaceutical Ltd acquire Aptose Biosciences?
Hanmi Pharmaceutical Ltd's acquisition of Aptose Biosciences was reported on July 1, 2026. Hanmi Pharmaceutical Co. Ltd. has completed the acquisition of Aptose Biosciences, Inc., acquiring all issued common shares not owned by Hanmi. Shareholders of Aptose will receive C$2.41 cash per share, marking a 28% premium. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Aptose Biosciences do?
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.